Results 91 to 100 of about 8,958 (210)

Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Shepeng Wei, Xuxu Xu, Jing Bao, Zhenjiang Pan   +3 more
wiley   +1 more source

Oncolytic virotherapy and microenvironment in multiple myeloma

, 2021
Multiple myeloma (MM) is a hematologic malignancy characterized by the accumulation of bone marrow (BM) clonal plasma cells, which are strictly dependent on the microenvironment.
Giuliani N., Federica Costa, Gaetano Donofrio, Marchica V., Donofrio G., Valentina Marchica, Costa F., Nicola Giuliani   +7 more
core   +1 more source

Tumor dynamics model with treatments by oncolytic virotherapy and MEK inhibitors involving TNF-α inhibitors: Stability analysis and optimal control

Computational and Mathematical Biophysics
Oncolytic virotherapy is one of the cancer treatments that kills cancer cells but leaves normal cells. Furthermore, mitogen-activated protein kinase (MEK) inhibitors boost chimeric antigen receptor expression and increase oncolytic virus entry into tumor
Daengkongkho Salinthip, Viriyapong Ratchada   +1 more
doaj   +1 more source

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Frontiers in Immunology, 2018
Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies.
Amanda Rosewell Shaw, Amanda Rosewell Shaw, Masataka Suzuki, Masataka Suzuki   +3 more
doaj   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment

Molecular Therapy: Oncolytics, 2018
Ewing sarcoma is a highly aggressive cancer that promotes the infiltration and activation of pro-tumor M2-like macrophages. Oncolytic virotherapy that selectively infects and destroys cancer cells is a promising option for treating Ewing sarcoma.
Nicholas L. Denton, Chun-Yu Chen, Brian Hutzen, Mark A. Currier, Thomas Scott, Brooke Nartker, Jennifer L. Leddon, Pin-Yi Wang, Rachelle Srinivas, Kevin A. Cassady, William F. Goins, Timothy P. Cripe   +11 more
doaj   +1 more source

Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.

PLoS Computational Biology, 2019
Oncolytic virotherapies, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects.
Tyler Cassidy, Morgan Craig
doaj   +1 more source

Principles and Practice Guidelines of Microbiota Medicine: Statements From the CHINAGUT Conference

Microbiota Medicine Research, Volume 1, Issue 1, Page 3-11, March 2026.
The 2025 CHINAGUT Conference convened a panel of 48 clinicians from 39 hospitals in 5 countries to develop 15 key statements, aimed at providing clinicians, educators, and healthcare administrators with a comprehensive framework to advance education, clinical practice, research, and public popularization in microbiota medicine.
Faming Zhang, Zheshun Pi, Sunny Hei Wong, Vineet Ahuja, Serena Porcari, Dai Ishikawa, Hailong Cao, Linlin Chen, Ning Chen, Xiong Chen, Bota Cui, Xiao Ding, Xingxiang He, Jia Hu, Jiang Jin, Ji Li, Weiwei Liao, Jingmei Liu, Ling Liu, Yanyan Liu, Yaping Liu, Yu Liu, Chen Lu, Gaochen Lu, Muhan Lv, Xiangjun Meng, Yongzhan Nie, Qian Ren, Lixuan Sang, Xin Sun, Yang Sun, Hongliang Tian, Baohong Wang, Honggang Wang, Liangjing Wang, Xin Wang, Weihong Wang, Zheyu Wang, Yanling Wei, Quan Wen, Lihao Wu, Xia Wu, Lijing Xiong, Guoliang Ye, Bo Yi, You Yu, Yue Zeng, Huihong Zhai, Ting Zhang, Zulun Zhang, Li Zhou, Li Zhu, Kaichun Wu   +52 more
wiley   +1 more source

Assessment and development of adenovirus type 11 for cancer therapy

, 2010
PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, virus and host immunity. The first generation of oncolytic adenoviruses, based on serotype 5 (Ad5), has achieved limited success in clinical trials.
Wong, Han Hsi
core  

Oncolytic viruses as anticancer vaccines

Frontiers in Oncology, 2014
Oncolytic virotherapy has shown impressive results in preclinical studies and first promising therapeutic outcomes in clinical trials as well. Since viruses are known for a long time as excellent vaccination agents, oncolytic viruses are now designed as ...
Norman eWoller, Engin eGürlevik, Cristina-Ileana eUreche, Anja eSchumacher, Florian eKühnel   +4 more
doaj   +1 more source